Payment overview · 2025
General Payments
$3,565.96
81 reported records · 28 companies
Healthcare provider profile · identity verified
David Y Lin, DO
Allopathic & Osteopathic Physicians|Internal Medicine · ROSEMEAD, CA · NPI 1679635353
Verified facts
What the public records show
CMS Open Payments records show David Y Lin, DO received $3,565.96 in general payments during 2025 across 81 reported records.
AstraZeneca Pharmaceuticals LP accounted for 12.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Gemtesa, Ingrezza, Jardiance, Kerendia, Linzess, Ozempic, Paxlovid, Rexulti, Rybelsus, Trelegy Ellipta, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 362 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 241 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 359 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Trelegy Ellipta by this doctor in 2024.
IRONWOOD PHARMACEUTICALS, INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Linzess as an associated drug or biological on 1209 records involving 1184 distinct recipient NPIs. Public Medicare Part D data also shows 362 claims for Linzess by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 359 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 2902 records involving 986 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Abilify Maintena by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rexulti by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Ingrezza by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 27924 records involving 10497 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Abilify Maintena by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 465 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported APTIOM as an associated drug or biological on 11 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Aptiom by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $448.46 | 12.6% | 12 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $442.30 | 12.4% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $318.52 | 8.9% | 10 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $222.59 | 6.2% | 6 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $165.09 | 4.6% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $163.39 | 4.6% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $158.63 | 4.5% | 7 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $156.05 | 4.4% | 3 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $150.00 | 4.2% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $125.00 | 3.5% | 1 | 2025 |
| VIVUS LLC | Unresolved — no canonical attribution shown | $125.00 | 3.5% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $124.99 | 3.5% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $124.98 | 3.5% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $121.83 | 3.4% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $121.83 | 3.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $111.44 | 3.1% | 5 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $97.67 | 2.7% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $90.64 | 2.5% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $46.52 | 1.3% | 2 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $42.05 | 1.2% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.46 | 0.9% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $29.75 | 0.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $26.20 | 0.7% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $26.11 | 0.7% | 1 | 2025 |
| IRONWOOD PHARMACEUTICALS, INC | Unresolved — no canonical attribution shown | $25.34 | 0.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $24.32 | 0.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $24.13 | 0.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.67 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,565.96 | 81 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $442.30 | 6 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $322.02 | 10 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $263.20 | 8 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $222.59 | 6 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $165.35 | 8 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $165.09 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $153.17 | 2 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $150.00 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| PANCREAZE Normalized: pancreaze |
Drug | VIVUS LLC | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $124.98 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $124.03 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $121.83 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $121.83 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $111.44 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $111.44 | 5 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $97.67 | 4 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $90.64 | 4 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC., IRONWOOD PHARMACEUTICALS, INC | $89.56 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $84.94 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $57.78 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $46.52 | 2 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $42.05 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $32.02 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $29.75 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $28.19 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $26.20 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $26.11 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $24.13 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.67 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 167 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 241 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 57 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 359 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 55 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 362 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 33 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 118 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 112 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 97 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
167 | 36 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
362 | 66 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
97 | 18 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
37 | 26 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
241 | 40 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
359 | 62 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
112 | 24 |
| IRONWOOD PHARMACEUTICALS, INC Exact reporting entity; no affiliate inference |
2025 | Linzess open payments reported associated product |
CMS Open Payments — General Payments 1209 supporting records · 1184 recipient NPIs · example record 1227653589 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
362 | 66 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
359 | 62 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 2902 supporting records · 986 recipient NPIs · example record 1251759994 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
118 | 20 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 27924 supporting records · 10497 recipient NPIs · example record 1227267721 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
465 | 57 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
33 | 33 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | APTIOM open payments reported associated product |
CMS Open Payments — General Payments 11 supporting records · 11 recipient NPIs · example record 1176658319 |
Aptiom · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
57 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2211 | 404 |
| Amlodipine Besylate | Amlodipine Besylate | 1794 | 351 |
| Losartan Potassium | Losartan Potassium | 1164 | 242 |
| Levothyroxine Sodium | Levothyroxine Sodium | 978 | 166 |
| Omeprazole | Omeprazole | 856 | 206 |
| Tamsulosin Hcl | Tamsulosin Hcl | 838 | 171 |
| Metformin Hcl | Metformin Hcl | 740 | 150 |
| Famotidine | Famotidine | 673 | 104 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 637 | 139 |
| Donepezil Hcl | Donepezil Hcl | 629 | 102 |
| Pantoprazole Sodium | Pantoprazole Sodium | 608 | 98 |
| Metoprolol Succinate | Metoprolol Succinate | 598 | 118 |
| Clopidogrel | Clopidogrel Bisulfate | 556 | 101 |
| Gabapentin | Gabapentin | 553 | 111 |
| Celecoxib | Celecoxib | 528 | 131 |
| Escitalopram Oxalate | Escitalopram Oxalate | 521 | 96 |
| Azithromycin | Azithromycin | 489 | 336 |
| Quetiapine Fumarate | Quetiapine Fumarate | 474 | 78 |
| Eliquis | Apixaban | 465 | 57 |
| Mirtazapine | Mirtazapine | 456 | 96 |
| Montelukast Sodium | Montelukast Sodium | 405 | 73 |
| Vascepa | Icosapent Ethyl | 387 | 70 |
| Linzess | Linaclotide | 362 | 66 |
| Atenolol | Atenolol | 359 | 66 |
| Jardiance | Empagliflozin | 359 | 62 |
| Memantine Hcl | Memantine Hcl | 352 | 42 |
| Alendronate Sodium | Alendronate Sodium | 343 | 55 |
| Fenofibrate | Fenofibrate Nanocrystallized | 336 | 61 |
| Potassium Chloride | Potassium Chloride | 329 | 52 |
| Furosemide | Furosemide | 314 | 52 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 313 | 102 |
| Simvastatin | Simvastatin | 300 | 47 |
| Trazodone Hcl | Trazodone Hcl | 294 | 52 |
| Levetiracetam | Levetiracetam | 292 | 29 |
| Clonidine Hcl | Clonidine Hcl | 281 | 84 |
| Cyclosporine | Cyclosporine | 275 | 62 |
| Lisinopril | Lisinopril | 267 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 258 | 85 |
| Metoprolol Tartrate | Metoprolol Tartrate | 247 | 39 |
| Meloxicam | Meloxicam | 244 | 55 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 244 | 115 |
| Farxiga | Dapagliflozin Propanediol | 241 | 40 |
| Sertraline Hcl | Sertraline Hcl | 238 | 33 |
| Baclofen | Baclofen | 223 | 56 |
| Tradjenta | Linagliptin | 213 | 27 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 208 | 38 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 202 | 58 |
| Carvedilol | Carvedilol | 200 | 30 |
| Finasteride | Finasteride | 198 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 190 | 25 |
| Olanzapine | Olanzapine | 183 | 25 |
| Ibuprofen | Ibuprofen | 181 | 81 |
| Icosapent Ethyl | Icosapent Ethyl | 178 | 57 |
| Raloxifene Hcl | Raloxifene Hcl | 178 | 37 |
| Hydralazine Hcl | Hydralazine Hcl | 177 | 34 |
| Divalproex Sodium | Divalproex Sodium | 172 | 27 |
| Pioglitazone Hcl | Pioglitazone Hcl | 172 | 38 |
| Risperidone | Risperidone | 170 | 26 |
| Creon | Lipase/Protease/Amylase | 167 | 36 |
| Restasis | Cyclosporine | 163 | 31 |
| Lorazepam | Lorazepam | 159 | 56 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 158 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 152 | 48 |
| Fluticasone Propionate | Fluticasone Propionate | 152 | 63 |
| Januvia | Sitagliptin Phosphate | 152 | 25 |
| Nitroglycerin | Nitroglycerin | 152 | 69 |
| Terazosin Hcl | Terazosin Hcl | 149 | 31 |
| Glimepiride | Glimepiride | 147 | 27 |
| Megestrol Acetate | Megestrol Acetate | 147 | 45 |
| Allopurinol | Allopurinol | 140 | 27 |
| Lactulose | Lactulose | 138 | 62 |
| Metformin Er Gastric | Metformin Hcl | 134 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 134 | 30 |
| Ezetimibe | Ezetimibe | 132 | 28 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 128 | 22 |
| Benztropine Mesylate | Benztropine Mesylate | 121 | 17 |
| Amoxicillin | Amoxicillin | 119 | 86 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 118 | 56 |
| Dexlansoprazole Dr | Dexlansoprazole | 118 | 28 |
| Rybelsus | Semaglutide | 118 | 20 |
| Amiodarone Hcl | Amiodarone Hcl | 114 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 112 | 24 |
| Azelastine Hcl | Azelastine Hcl | 111 | 25 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 111 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 106 | 46 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 106 | 15 |
| Albuterol Sulfate | Albuterol Sulfate | 105 | 13 |
| Clonazepam | Clonazepam | 105 | 22 |
| Glipizide | Glipizide | 104 | 26 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 101 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 101 | 24 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 99 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 98 | 13 |
| Memantine Hcl Er | Memantine Hcl | 98 | 17 |
| Bethanechol Chloride | Bethanechol Chloride | 97 | 21 |
| Zenpep | Lipase/Protease/Amylase | 97 | 18 |
| Dutasteride | Dutasteride | 95 | 17 |
| Tramadol Hcl | Tramadol Hcl | 95 | 25 |
| Valsartan | Valsartan | 95 | 19 |
| Hydrocortisone | Hydrocortisone | 93 | 39 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 92 | 28 |
| Benazepril Hcl | Benazepril Hcl | 90 | 17 |
| Myrbetriq | Mirabegron | 89 | 19 |
| Levofloxacin | Levofloxacin | 88 | 74 |
| Oxybutynin Chloride | Oxybutynin Chloride | 88 | suppressed |
| Cephalexin | Cephalexin | 87 | 74 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 87 | 17 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 83 | 50 |
| Ketoconazole | Ketoconazole | 81 | 19 |
| Aripiprazole | Aripiprazole | 79 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 75 | suppressed |
| Fluocinonide | Fluocinonide | 72 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 71 | suppressed |
| Entresto | Sacubitril/Valsartan | 71 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 69 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 69 | 38 |
| Latanoprost | Latanoprost | 68 | 22 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 67 | 21 |
| Nifedipine Er | Nifedipine | 67 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 64 | suppressed |
| Topiramate | Topiramate | 64 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 60 | 15 |
| Humulin R | Insulin Regular, Human | 60 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 58 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 58 | 15 |
| Alprazolam | Alprazolam | 57 | suppressed |
| Gemtesa | Vibegron | 57 | suppressed |
| Xarelto | Rivaroxaban | 57 | 11 |
| Midodrine Hcl | Midodrine Hcl | 56 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 55 | 11 |
| Kerendia | Finerenone | 55 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 54 | 20 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 54 | 13 |
| Haloperidol | Haloperidol | 53 | suppressed |
| Spironolactone | Spironolactone | 53 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 52 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 52 | 16 |
| Clonidine | Clonidine | 51 | suppressed |
| Digoxin | Digoxin | 50 | suppressed |
| Temazepam | Temazepam | 48 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 48 | suppressed |
| Lamotrigine | Lamotrigine | 47 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 47 | 13 |
| Lacosamide | Lacosamide | 45 | suppressed |
| Clarithromycin | Clarithromycin | 44 | 39 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 44 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 43 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 43 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 43 | 36 |
| Novolin R | Insulin Regular, Human | 43 | 14 |
| Novolin R Flexpen | Insulin Regular, Human | 43 | 14 |
| Dapagliflozin | Dapagliflozin Propanediol | 42 | 15 |
| Prednisone | Prednisone | 42 | 21 |
| Enoxaparin Sodium | Enoxaparin Sodium | 41 | suppressed |
| Lidocaine | Lidocaine | 41 | 11 |
| Gemfibrozil | Gemfibrozil | 40 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 40 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 39 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 39 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 38 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 38 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 38 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 38 | suppressed |
| Loperamide | Loperamide Hcl | 37 | 31 |
| Prolia | Denosumab | 37 | 26 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 36 | suppressed |
| Lumigan | Bimatoprost | 36 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 35 | 13 |
| Lovastatin | Lovastatin | 35 | suppressed |
| Folic Acid | Folic Acid | 34 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 34 | 28 |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 34 | 25 |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 33 | suppressed |
| Lansoprazole | Lansoprazole | 33 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 33 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 33 | 33 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 33 | 28 |
| Brilinta | Ticagrelor | 32 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 32 | suppressed |
| Misoprostol | Misoprostol | 32 | suppressed |
| Procto-Med Hc | Hydrocortisone | 32 | 17 |
| Sucralfate | Sucralfate | 32 | suppressed |
| Mupirocin | Mupirocin | 31 | 15 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 30 | 17 |
| Ranolazine Er | Ranolazine | 29 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 29 | suppressed |
| Methimazole | Methimazole | 28 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 28 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 28 | 12 |
| Ursodiol | Ursodiol | 28 | suppressed |
| Budesonide | Budesonide | 27 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 27 | suppressed |
| Entecavir | Entecavir | 27 | suppressed |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Irbesartan | Irbesartan | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Amantadine | Amantadine Hcl | 26 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 26 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 26 | 14 |
| Glycopyrrolate | Glycopyrrolate | 25 | suppressed |
| Levemir Flexpen | Insulin Detemir | 25 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 25 | suppressed |
| Novolog Flexpen | Insulin Aspart | 25 | suppressed |
| Ozempic | Semaglutide | 25 | suppressed |
| Repaglinide | Repaglinide | 25 | suppressed |
| Exemestane | Exemestane | 24 | suppressed |
| Nystatin | Nystatin | 24 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 24 | suppressed |
| Acarbose | Acarbose | 23 | suppressed |
| Ciclopirox | Ciclopirox | 23 | 13 |
| Labetalol Hcl | Labetalol Hcl | 23 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 23 | 12 |
| Repatha Sureclick | Evolocumab | 23 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Enulose | Lactulose | 22 | suppressed |
| Sevelamer Hcl | Sevelamer Hcl | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Calcium Acetate | Calcium Acetate | 21 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 21 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 21 | suppressed |
| Levemir | Insulin Detemir | 21 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Rivastigmine | Rivastigmine | 21 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 21 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 20 | suppressed |
| Febuxostat | Febuxostat | 20 | suppressed |
| Levocarnitine | Levocarnitine | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 19 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 19 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 19 | suppressed |
| Epogen | Epoetin Alfa | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Ingrezza | Valbenazine Tosylate | 19 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 19 | 15 |
| Pentoxifylline | Pentoxifylline | 19 | suppressed |
| Rexulti | Brexpiprazole | 19 | suppressed |
| Rhopressa | Netarsudil Mesylate | 19 | suppressed |
| Travoprost | Travoprost | 19 | suppressed |
| Xiidra | Lifitegrast | 19 | suppressed |
| Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 18 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 18 | suppressed |
| Phenobarbital | Phenobarbital | 18 | suppressed |
| Ssd | Silver Sulfadiazine | 18 | 12 |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 17 | 16 |
| Scopolamine | Scopolamine | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 15 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 16 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Olanzapine Odt | Olanzapine | 15 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 15 | suppressed |
| Valproic Acid | Valproic Acid | 15 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 13 | suppressed |
| Bepotastine Besilate | Bepotastine Besilate | 13 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 13 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 13 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Trospium Chloride | Trospium Chloride | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 13 | suppressed |
| Zonisamide | Zonisamide | 13 | suppressed |
| Abilify Maintena | Aripiprazole | 12 | suppressed |
| Asenapine Maleate | Asenapine Maleate | 12 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Livalo | Pitavastatin Calcium | 12 | suppressed |
| Lofena | Diclofenac Potassium | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 12 | suppressed |
| Norliqva | Amlodipine Besylate | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | 11 |
| Xcopri | Cenobamate | 12 | suppressed |
| Dorzolamide-Timolol | Dorzolamide/Timolol/Pf | 11 | suppressed |
| Epinastine Hcl | Epinastine Hcl | 11 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 11 | suppressed |
| Mexiletine Hcl | Mexiletine Hcl | 11 | suppressed |
| Norethindrone-E.Estradiol-Iron | Norethindrone-E.Estradiol-Iron | 11 | suppressed |
| Proair Respiclick | Albuterol Sulfate | 11 | suppressed |
| Prolensa | Bromfenac Sodium | 11 | suppressed |
| Roflumilast | Roflumilast | 11 | suppressed |
| Rufinamide | Rufinamide | 11 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 11 | suppressed |
| Timolol Maleate | Timolol Maleate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,565.96 · 81 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, AUSTEDO XR, BREZTRI, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, FARXIGA, GEMTESA, INGREZZA, JARDIANCE, Kerendia, Korlym, LINZESS, Leqembi, NURTEC ODT, Nayzilam, OTEZLA, Ozempic, PANCREAZE, PAXLOVID, REPATHA, REXULTI, REZDIFFRA, Rybelsus, Symbravo, TRELEGY ELLIPTA, VERQUVO, VOQUEZNA, ZAVZPRET, ZENPEP, ZORYVE | 27 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error